Figure 3
Figure 3. CR2Fc enhances mAb therapy in SCID beige mice. Survival of SCID beige mice challenged with EL4 cells and treated with 14G2a alone or in combination with CR2Fc. Long-term survival of mice treated with mAb and CR2Fc is significantly extended compared with mice treated with mAb therapy alone; n = 8 or 9.

CR2Fc enhances mAb therapy in SCID beige mice. Survival of SCID beige mice challenged with EL4 cells and treated with 14G2a alone or in combination with CR2Fc. Long-term survival of mice treated with mAb and CR2Fc is significantly extended compared with mice treated with mAb therapy alone; n = 8 or 9.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal